Literature DB >> 3928803

Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.

F Herrmann, S A Cannistra, H Levine, J D Griffin.   

Abstract

Gamma interferon induced surface expression of interleukin 2 (IL-2) receptors on normal human monocytes and the monocytoid cell lines U937 and HL60. These receptors were detected by anti-IL-2 receptor monoclonal antibodies, and U937 IL-2 receptors were indistinguishable from T lymphocyte IL-2 receptors by immunoprecipitation. Also, U937 IL-2 receptors bound biologically active IL-2. These results suggest a role for monocyte IL-2 receptors in T cell/monocyte interaction during an immune response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928803      PMCID: PMC2187806          DOI: 10.1084/jem.162.3.1111

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

1.  Activation of human thymocytes via the 50KD T11 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; A Bensussan; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

2.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; O Acuto; C Poole; L Palley; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

3.  Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells.

Authors:  H E Broxmeyer; L Lu; E Platzer; C Feit; L Juliano; B Y Rubin
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients.

Authors:  J D Griffin; R P Beveridge; S F Schlossman
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

6.  Prostaglandins modulate macrophage Ia expression.

Authors:  D S Snyder; D I Beller; E R Unanue
Journal:  Nature       Date:  1982-09-09       Impact factor: 49.962

7.  MIF-like activity of natural and recombinant human interferon-gamma and their neutralization by monoclonal antibody.

Authors:  G B Thurman; I A Braude; P W Gray; R K Oldham; H C Stevenson
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Detection and functional studies of p60-65 (Tac antigen) on activated human B cells.

Authors:  L K Jung; T Hara; S M Fu
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

9.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway.

Authors:  B Perussia; E T Dayton; V Fanning; P Thiagarajan; J Hoxie; G Trinchieri
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

  10 in total
  61 in total

Review 1.  Polypeptides controlling hematopoietic cell development and activation. I. In vitro results.

Authors:  F Herrmann; R Mertelsmann
Journal:  Blut       Date:  1989-03

Review 2.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Functional surface structures on human natural killer cells.

Authors:  R E Schmidt; T Hercend; S F Schlossman; J Ritz
Journal:  Klin Wochenschr       Date:  1985-12-02

4.  Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.

Authors:  Z Toossi; J R Sedor; J P Lapurga; R J Ondash; J J Ellner
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Recombinant interleukin-1 alpha, interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1.

Authors:  C Berkowitz; Y Becker
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Interferon-gamma enhances monocyte cytotoxicity via enhanced reactive oxygen intermediate production. Absence of an effect on macrophage cytotoxicity is due to failure to enhance reactive nitrogen intermediate production.

Authors:  J H Martin; S W Edwards
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 8.  The role of free oxygen radicals in the expulsion of primary infections of Nippostrongylus brasiliensis.

Authors:  N C Smith
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

9.  The expression of functional IL-2 receptor on activated macrophages depends on the stimulus applied.

Authors:  S Valitutti; A Carbone; F Castellino; N Maggiano; R Ricci; L M Larocca; P Musiani
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

10.  LW/SO cell line: a tool for studying the phenotypical characterization and commitment of hematopoietic stem cells.

Authors:  S Oez; U Trautmann; M Smetak; J Birkmann; S al salemeh; E Gebhart; W M Gallmeier
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.